{"id":16894,"date":"2026-06-27T21:01:00","date_gmt":"2026-06-27T13:01:00","guid":{"rendered":"https:\/\/vaxlab.dukekunshan.edu.cn\/?post_type=project-news&p=16894"},"modified":"2026-09-08T16:44:55","modified_gmt":"2026-09-08T08:44:55","slug":"evidence-and-policy-translation-of-fractional-dose-pneumococcal-conjugate-vaccination","status":"publish","type":"project-news","link":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/project-news\/evidence-and-policy-translation-of-fractional-dose-pneumococcal-conjugate-vaccination\/","title":{"rendered":"Evidence and Policy Translation of Fractional-Dose Pneumococcal Conjugate Vaccination"},"content":{"rendered":"\n

Streptococcus pneumoniae<\/em> remains a leading cause of pneumonia, meningitis, and sepsis among children under five years of age. The widespread introduction of pneumococcal conjugate vaccines (PCVs) into national immunization programs has substantially reduced the global burden of pneumococcal disease. However, maintaining high vaccine coverage remains challenging in many low- and middle-income countries because of financial constraints, high vaccine prices, and the gradual withdrawal of international donor support. Consequently, optimizing PCV immunization schedules while preserving protective effectiveness has become an important policy priority.<\/p>\n\n\n\n

A landmark randomized non-inferiority trial conducted in Kenya and published in The New England Journal of Medicine<\/em> in 2024 provided the first robust evidence supporting the use of fractional-dose PCV13. The trial enrolled 2,100 healthy infants who received either full-dose or fractional-dose PCV13 or PCV10 under a 2+1 schedule. Immune responses were evaluated after primary and booster vaccination. The study demonstrated that a 40% dose of PCV13 achieved non-inferior immunogenicity compared with the standard full dose for nearly all serotypes after primary vaccination and for all serotypes following the booster dose. In contrast, 20% fractional-dose PCV13 and 40% fractional-dose PCV10 failed to meet the predefined non-inferiority criteria. Importantly, fractional-dose PCV13 showed no increase in serious adverse events, while fractional-dose PCV10 was associated with higher vaccine-type pneumococcal carriage at 18 months.<\/p>\n\n\n\n

To further investigate these findings, a nested analysis published in Vaccine<\/em> in 2026 examined the dose\u2013response relationship across individual pneumococcal serotypes. The analysis revealed substantial heterogeneity in immune responses. Several PCV13 serotypes exhibited plateau-shaped dose\u2013response curves, suggesting that moderate antigen reduction had limited effects on immunogenicity, whereas others, including serotypes 14, 18C, and 19F, remained dose-dependent and were more susceptible to reduced immune responses. These findings indicate that fractional-dose strategies should consider serotype-specific characteristics rather than relying solely on overall immunogenicity outcomes, particularly in regions where certain serotypes contribute disproportionately to disease burden.<\/p>\n\n\n\n

The accumulating evidence directly informed the World Health Organization\u2019s updated 2025 position paper on PCVs. Rather than replacing the standard three-dose schedule, WHO recommends fractional-dose PCV13 only as an optional strategy for mature immunization programs that satisfy strict implementation criteria. These include sustained high vaccination coverage, established herd immunity, the capacity to deliver booster doses, and robust surveillance systems capable of detecting changes in pneumococcal disease epidemiology. WHO also recommends that countries establish contingency plans to promptly restore full-dose vaccination if coverage declines or vaccine-type disease resurges.<\/p>\n\n\n\n

From a policy perspective, fractional-dose PCV13 represents an evidence-based approach to improving the sustainability of immunization programs under financial pressure. Nevertheless, current evidence supports only the 40% fractional-dose PCV13 strategy and should not be extrapolated to other PCV products or immunocompromised populations. Successful implementation requires balancing product-specific evidence, local serotype distribution, vaccination coverage, program capacity, and disease surveillance to ensure that cost savings are achieved without compromising long-term public health benefits.<\/p>\n\n\n\n

\n\n\n\n

Relevant Research and Evidence Updates:<\/p>\n\n\n\n

[1] Martinez-de-Albeniz I, Bottomley C, Lucinde R, Kaniu MW, Badaud S, Mutahi M, et al. Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial. Vaccine. 2026 Feb 15;73:128186. doi: 10.1016\/j.vaccine.2025.128186. Epub 2026 Jan 6. PMID: 41500002.<\/p>\n\n\n\n

[2] Gallagher KE, Lucinde R, Bottomley C, Kaniu M, Suaad B, Mutahi M, et al. Fractional Doses of Pneumococcal Conjugate Vaccine – A Noninferiority Trial. N Engl J Med. 2024 Nov 28;391(21):2003-2013. doi: 10.1056\/NEJMoa2314620. Epub 2024 Sep 26. PMID: 39330966; PMCID: PMC7616702.<\/p>\n\n\n\n

[3] World Health Organization. WHO position paper: Pneumococcal conjugate vaccines in infants and children aged <5 years – September 2025. Wkly Epidemiol Rec. 2025;100(39):411-437.<\/p>\n\n\n\n

[4] World Health Organization. (2025). Report: Pneumococcal conjugate vaccine reduced dosing schedule: a systematic review and meta-analysis. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/sage\/vpp-background-documents\/report_who_pcv_1_1.pdf?sfvrsn=197716b7_3&download=true<\/p>\n\n\n\n

\n\n\n\n

Translating and summarizing: Tianyi Deng<\/p>\n\n\n\n

Layout editing by: Ruitong Li<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Streptococcus pneumoniae remains a leading cause of pneumonia, meningitis, and sepsis among children under five years of age. The widespread introduction of pneumococcal conjugate vaccines (PCVs) into national immunization programs has substantially reduced the global burden of pneumococcal disease. However, maintaining high vaccine coverage remains challenging in many low- and middle-income countries because of financial constraints, […]<\/p>\n","protected":false},"featured_media":16694,"menu_order":0,"template":"","meta":{"type_label":"none_selected"},"news-category":[73],"class_list":["post-16894","project-news","type-project-news","status-publish","has-post-thumbnail","hentry","news-category-research-en"],"_links":{"self":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/project-news\/16894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/project-news"}],"about":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/types\/project-news"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media\/16694"}],"wp:attachment":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media?parent=16894"}],"wp:term":[{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/news-category?post=16894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}